Since September 2024, the FDA requires every mammography facility in the United States to tell patients directly on their mammogram report whether their breasts are dense, using standardized lay language.1 This replaced a patchwork of state laws with a national floor, and it means roughly 40–50% of your patients receiving mammograms now receive a letter telling them they have dense breasts — and many will call you about it.
The clinically important point to hold onto is that density is both a masking problem and a modest risk factor for breast cancer, and these are two separate issues. Dense breast tissue absorbs x-rays much like a tumor does, so both dense breast tissue and tumors appear white on a mammogram. In women with dense breast tissue, breast cancer can be more easily camouflaged against the dense tissue. Reported sensitivity of mammograms falls off sharply as breast density rises: sensitivity of mammograms for average-density breasts is about 81-90%, whereas sensitivity can drop to 55-65% in dense breast tissue, and even lower in the densest tissue.
Density is also an independent biological risk factor. Compared with women of average density, those in the two densest categories have roughly 1.2 to 2.1x the lifetime risk of breast cancer. But under current NCCN guidance, density alone does not qualify a patient for screening MRI — it is a risk factor to feed into a risk model, not a standalone indication.2
What actually changed
Before September 2024, breast density notification was governed state by state — a majority of states had some form of notification law, with substantial variation in what had to be disclosed and whether supplemental screening coverage was mandated. Several states only required facilities to hand out general educational information about breast density as a concept, without actually telling the patient directly whether they had dense breast tissue. On top of that, several states had no density notification law whatsoever. The FDA's amendment to the Mammography Quality Standards Act regulations created a national requirement with specific mandated language, so every patient now gets a density statement regardless of where she is screened.1
What the federal rule did not do is mandate insurance coverage for supplemental screening, or tell clinicians what to do next. That gap — a patient with a notification letter and no clear pathway — is the practical problem addressed here.
A separate federal action has since narrowed part of that coverage gap — see "Is supplemental screening covered by insurance?" below.9
The four BI-RADS density categories
| Category | Description | Clinical implication |
|---|---|---|
| a | Almost entirely fatty | Not "dense" for notification. Mammographic sensitivity high. |
| b | Scattered fibroglandular | Not "dense" for notification. No supplemental screening on density grounds. |
| c | Heterogeneously dense | Triggers notification. Masking effect meaningful. Feed into risk model; consider supplemental if other risk factors present. |
| d | Extremely dense | Triggers notification. Greatest masking effect and highest density-attributable relative risk. Strongest case for supplemental screening discussion. |
Categories c and d together are what the notification rule calls "dense," and they account for roughly 40–50% of the screening population.3 One thing worth telling patients explicitly: density is assessed visually by the interpreting radiologist and it is not a fixed trait. It typically decreases with age and after menopause, so a category-c result at 45 may read as category b at 60.
Supplemental screening options — and when each fits
Digital breast tomosynthesis (DBT/3D Mammography). Now largely standard of care rather than "supplemental." Improves cancer detection and reduces recall rates relative to 2D mammography, with the benefit most pronounced in dense tissue. If your patient is still receiving 2D-only mammography, moving her to DBT is the first and easiest intervention.4 The guideline bodies don't fully agree here either: USPSTF treats 2D and 3D as equally effective and takes no preference, while ACR and ASBrS state that 3D tomosynthesis is the preferred sole modality for average-risk women, regardless of density category.67
Breast MRI. The most sensitive option, and the right answer for patients who meet NCCN high-risk criteria — which density alone does not satisfy. If your patient with dense breast tissue also has a family history of breast cancer, a known variant, prior chest radiation, or a ≥20% lifetime risk by Tyrer-Cuzick, she qualifies on those grounds and MRI is indicated. Density is one input to that calculation, not a substitute for it.2
Whole-breast ultrasound. Adds incremental cancer detection in dense breasts, but with a substantially higher false-positive and short-interval-follow-up rate. Reasonable for an average-risk dense-breast patient who wants supplemental screening and cannot have or does not qualify for MRI — provided she is counseled on the false-positive trade-off.3
Contrast-enhanced mammography (CEM). An emerging option with sensitivity approaching MRI in some series, better availability, and lower cost — but it requires iodinated contrast and coverage is inconsistent. Availability varies considerably by market. Worth knowing about; check what your local imaging centers actually offer.
The guideline problem — and what to do when your patient doesn't fit neatly
Here's what makes this harder than it should be: there is no single "the guidelines" for dense breast screening. USPSTF, ACS, ACR/SBI/ASBrS, and NCCN don't fully agree with each other267 — not just on screening interval and starting age (that fight is public and ongoing), but specifically on what density itself should trigger.
NCCN's screening guideline gates MRI on a calculated risk score: a validated model has to put your patient at ≥20–25% lifetime risk2 (or, as of the 2026 update, a 5-year Gail model risk ≥1.7%8, a newer secondary criterion aimed at older women whose lifetime-risk number mechanically drops with age even as their near-term risk stays elevated). Density feeds into that calculation through models like Tyrer-Cuzick, BOADICEA, or BCSC — but on its own, it doesn't qualify the patient for a breast MRI.
ACR's own Appropriateness Criteria — a separate document from the NCCN screening guideline — is more aggressive, and splits by density category rather than gating everything on a risk score. For heterogeneously dense breasts (Category C), it rates supplemental ultrasound and MRI both as "may be appropriate" — reasonable to offer, not a strong default. For extremely dense breasts (Category D), it rates MRI as "usually appropriate," full stop — even for a patient who is otherwise average risk and doesn't meet NCCN's 20% threshold.3
So: if your patient is average risk, has dense breast tissue, and does not qualify for MRI under NCCN's risk-model threshold, here's the practical path:
First, confirm the "doesn't qualify" conclusion actually came from a formal risk assessment using a density-inclusive model — not an assumption based on the density result alone. Gabbi's risk assessment (see the referral link below) does this automatically.
Second, make sure she's on annual DBT rather than 2D-only mammography — that's the one recommendation everybody agrees on, and it's the highest-yield, lowest-friction change available.
Third, for Category C: offer whole-breast ultrasound as a reasonable supplemental option through shared decision-making, with clear counseling on the higher callback and false-positive rate that comes with it.
Fourth, for Category D specifically: have the MRI conversation anyway. ACR's Appropriateness Criteria supports ordering it even though she doesn't meet NCCN's gated threshold3 — you're not going off-guideline, you're following a different, equally legitimate guideline than the one that said "no." Document which criteria you're following when you order it, since a payer or reviewer may ask.
Fifth, check coverage before you order anything supplemental. The notification rule itself didn't mandate insurance coverage, and state-level coverage mandates for supplemental screening are a separate patchwork from the notification-law patchwork covered earlier in this article. That picture has partly changed: a federal rule effective January 1, 2026 now requires most health plans, including self-funded ones that state law can't reach, to cover clinically indicated additional imaging at no cost.10 Coverage is broader than it was, but it's still not unconditional — check the specific plan.
Three things that get missed
Reflexively ordering MRI off a notification letter. This is now the most common density-related error in primary care. A density notification is not an MRI indication. Run the risk model; if she crosses the threshold on the full picture, order it. If she does not, MRI is not the answer and will generate false positives and cost without guideline support.2
Letting the patient believe density means abnormality. Patients routinely read "dense breast tissue" as a finding, a pre-cancerous state, or something they did wrong. It is an anatomic description that applies to nearly half of screened women. Naming that directly resolves most of the anxiety related to this concern.
Not feeding density into the risk model. Density is a legitimate input to Tyrer-Cuzick, and omitting it means the model under-reads risk in exactly the population the notification identified. If you have a BI-RADS density category, put it in the risk model.5
What to tell your patient — in one paragraph
Something close to: "Dense breast tissue means the mammogram shows more glandular and connective tissue relative to fat. It is very common — close to half of women get this result — and it is not an abnormality or a finding of anything wrong. It matters for two reasons: it can make mammograms harder to read, and it slightly raises breast cancer risk on its own. What we do about it depends on your overall risk picture, not the density result by itself. Let's run a formal risk assessment and decide from there."
Gabbi runs the full risk assessment with density included, and returns a screening plan — not just a number.
Frequently asked questions
Does dense breast tissue mean my patient needs an MRI?
No — not on density alone. Under current NCCN guidance, screening MRI is indicated for patients who meet high-risk criteria (known pathogenic variant, untested first-degree relative of a carrier, ≥20% lifetime risk by a validated model, or prior chest radiation). Density is an input to the risk calculation, not an independent indication.2
How much does density actually raise risk?
Extremely dense tissue (category d) carries a modestly elevated relative risk compared with average density — meaningful in a risk model, but on its own well below the threshold that changes screening strategy. It is a contributing factor, not a driver.3
Is supplemental screening covered by insurance?
More often than it used to be, though still not universal. The federal notification rule itself did not mandate coverage.1 Separately, roughly 40-plus states mandate insurance coverage for supplemental breast imaging (ultrasound and/or MRI) for dense breasts — most eliminate cost-sharing entirely, though a few states still allow copays or deductibles. The long-standing gap in state law is that it doesn't reach self-funded ERISA employer plans, which cover a large share of employees.9
That gap narrowed as of January 1, 2026: updated federal HRSA guidance under the ACA's preventive services mandate now requires non-grandfathered group health plans and insurers — including self-funded ERISA plans — to cover additional imaging (MRI, ultrasound, extra mammographic views) and related pathology at no cost-sharing when clinically needed to complete the screening process. It isn't an unconditional density-triggered mandate — coverage still depends on clinical indication, with density as one relevant factor — but it closes much of the self-funded-plan gap state laws left open.10 A further bill, the Find It Early Act, would go beyond that and require all plans to cover breast imaging at no cost for women with dense breasts or elevated risk regardless of clinical indication; as of this writing it has been introduced in Congress but has not passed.11
Bottom line for your patients: check both her state's law and, since 2026, whether her plan is now subject to the federal no-cost-sharing requirement. Coverage is meaningfully broader than it was, but not standardized.
Can density change over time?
Yes. Density generally decreases with age and after menopause, and hormone therapy can increase it. Assessment is also somewhat subjective between readers. A single density category is a snapshot, not a permanent classification.3
Sources
- U.S. Food and Drug Administration. Mammography Quality Standards Act; Final Rule amending 21 CFR Part 900. Compliance date September 10, 2024.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis, Version 3.2025.
- American College of Radiology. ACR Appropriateness Criteria: Supplemental Breast Cancer Screening Based on Breast Density (2024 update). Also: DenseBreast-info.org clinician resources.
- Friedewald SM et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA 2014;311:2499-2507.
- Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-1130. Density incorporated in IBIS v8.
- U.S. Preventive Services Task Force. Screening for Breast Cancer: Recommendation Statement. 2024.
- American Society of Breast Surgeons. Position Statement on Screening Mammography. 2026.
- DenseBreast-info, Inc. New NCCN Guidelines Add 5-Year Risk to Breast Screening: What It Means for Your Patients. 2026.
- DenseBreast-info, Inc. State Law Insurance Map. Accessed 2026.
- Segal. New Requirements for Breast and Cervical Cancer Screening (summarizing the HRSA Women's Preventive Services Guidelines update, effective January 1, 2026). Also: Mercer, 2026 ACA Update: Expanded Breast Cancer Screenings.
- Find It Early Act, S.1410 / 119th Congress and H.R.6182 / 119th Congress (introduced; not enacted as of this writing).
This article is written for licensed clinicians and does not constitute medical advice for patients. Guidelines evolve — verify against the current source before making a clinical decision. State density-notification and coverage law varies and changes — verify local requirements.